GSK, Yale University enter into drug discovery alliance

Under the collaboration, GSK integrates its expertise in medicinal chemistry with Yale’s work on proteolysis targeting chimeric molecules (PROTACs).

The PROTAC technology directs disease-causing proteins to a cell’s garbage disposal where they can be destroyed.

Yale will be eligible for milestone and royalty payments for each protein-degrading drug that is discovered and developed, as per the agreement.

GSK Protein Degradation effort head Kris Famm said, "This partnership is exploring a new way for promising, but unproven therapeutic approaches to jump from the academic lab more quickly into the early stage pharmaceutical pipeline,"